
COVID19- South America: Gilead block access to coronavirus treatment for 440 million people
Buenos Aires, May 12th 2020. Yesterday the american company Gilead Sciences signed non exclusive voluntary licenses with five generic manufacturers from…
25 news articles and releases.
Page 1 of 3

Buenos Aires, May 12th 2020. Yesterday the american company Gilead Sciences signed non exclusive voluntary licenses with five generic manufacturers from…

Between October 12th and 19th, RedLAM is in Geneva participating of the “Week of Peoples”, a wake up call to social movements worldwide to contribute to the…

Fundación GEP filed an opposition to the patent application claimed by Gilead over the combination Sofosbuvir + Velpatasvir. This is the third opposition…
From Fundación GEP , we express our harsh condemnation, and warn the population about the measure announced today by the argentine President, Mauricio…

Buenos Aires, July 6 2018. In a context of economic crisis of magnitude that Argentina is facing there are stockouts of essential medicines. According to…

Argentina has made an important step forward to protect local production of generics of an essential medicine to treat Hepatitis C. This brings significant…

The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por:…

The Argentinian National Institute of Industrial Property (INPI, by its acronym in Spanish) signed a bilateral agreement with the US Patent Office on…

Por: Julia Varela BUENOS AIRES, February 14, 2017 - The GEP Foundation and Intiative for Medicines, Access and Knowledge (IMAK) filed yesterday an…

International Congress on Access to Medicines and Human Rights' Full Schedule – Fundación GEP.